Next Article in Journal
Tumor Microenvironment, a Paradigm in Hepatocellular Carcinoma Progression and Therapy
Next Article in Special Issue
PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression
Previous Article in Journal
An In Silico Identification of Common Putative Vaccine Candidates against Treponema pallidum: A Reverse Vaccinology and Subtractive Genomics Based Approach
Previous Article in Special Issue
Expansion of T Cells with Interleukin-21 for Adoptive Immunotherapy of Murine Mammary Carcinoma
Open AccessReview

Promising Targets for Cancer Immunotherapy: TLRs, RLRs, and STING-Mediated Innate Immune Pathways

School of Life Science and Technology, Harbin Institute of Technology, Harbin 150080, China
*
Author to whom correspondence should be addressed.
Academic Editor: William Chi-shing Cho
Int. J. Mol. Sci. 2017, 18(2), 404; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms18020404
Received: 23 December 2016 / Revised: 7 February 2017 / Accepted: 7 February 2017 / Published: 14 February 2017
(This article belongs to the Special Issue Targeting Immune Checkpoints and Immunotherapy)
Malignant cancers employ diverse and intricate immune evasion strategies, which lead to inadequately effective responses of many clinical cancer therapies. However, emerging data suggest that activation of the tolerant innate immune system in cancer patients is able, at least partially, to counteract tumor-induced immunosuppression, which indicates triggering of the innate immune response as a novel immunotherapeutic strategy may result in improved therapeutic outcomes for cancer patients. The promising innate immune targets include Toll-like Receptors (TLRs), RIG-I-like Receptors (RLRs), and Stimulator of Interferon Genes (STING). This review discusses the antitumor properties of TLRs, RLRs, and STING-mediated innate immune pathways, as well as the promising innate immune targets for potential application in cancer immunotherapy. View Full-Text
Keywords: cancer immunotherapy; innate immunity; Toll-like Receptors; RIG-I-like Receptors; Stimulator of Interferon Genes cancer immunotherapy; innate immunity; Toll-like Receptors; RIG-I-like Receptors; Stimulator of Interferon Genes
Show Figures

Graphical abstract

MDPI and ACS Style

Li, K.; Qu, S.; Chen, X.; Wu, Q.; Shi, M. Promising Targets for Cancer Immunotherapy: TLRs, RLRs, and STING-Mediated Innate Immune Pathways. Int. J. Mol. Sci. 2017, 18, 404. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms18020404

AMA Style

Li K, Qu S, Chen X, Wu Q, Shi M. Promising Targets for Cancer Immunotherapy: TLRs, RLRs, and STING-Mediated Innate Immune Pathways. International Journal of Molecular Sciences. 2017; 18(2):404. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms18020404

Chicago/Turabian Style

Li, Kai; Qu, Shuai; Chen, Xi; Wu, Qiong; Shi, Ming. 2017. "Promising Targets for Cancer Immunotherapy: TLRs, RLRs, and STING-Mediated Innate Immune Pathways" Int. J. Mol. Sci. 18, no. 2: 404. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms18020404

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop